Mod­er­na turns to Asia, plots new hires as it pon­ders $35B+ Covid-19 vac­cine wind­fall

In a con­tin­ued push to plant its flags around the world, Mod­er­na un­veiled plans to set up branch­es in Hong Kong, Sin­ga­pore, Tai­wan and Malaysia as key re­gion­al of­fices serv­ing the Asian mar­ket.

The mR­NA play­er — whose wild­ly suc­cess­ful Covid-19 vac­cine trans­formed it from a house­hold name in biotech to a house­hold name, pe­ri­od — cur­rent­ly has lim­it­ed pres­ence in­ter­na­tion­al­ly. Its sub­sidiaries in South Ko­rea, Japan and Aus­tralia em­ploy on­ly 24 staffers com­bined. Just days ago, word got out that Mod­er­na is putting the fin­ish­ing touch­es to a deal to build out new R&D and man­u­fac­tur­ing fa­cil­i­ties in the UK.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER